As of January 22, 2025, Genelux (GNLX) has a market cap of $0.11 billion USD. According to our data, Genelux is ranked No.7620 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.11 B |
33.47%
|
Dec 31, 2024 | $81.51 M |
-83.15%
|
Dec 29, 2023 | $0.48 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.79 B |
-0.003 M
|
USA
|
Merck
MRK
|
$242.04 B |
-0.000 M
|
USA
|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
Johnson & Johnson
JNJ
|
$349.75 B |
0.001 M
|
USA
|
Novartis
NVS
|
$196.27 B |
-0.007 M
|
Switzerland
|
AbbVie
ABBV
|
$299.00 B |
-0.007 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Market Cap | = | GNLX Stock Price | * | GNLX Shares Outstanding |
= | $3.15 | * | 34.54 M | |
= | $0.11 B |